Cargando…

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR

Ibrutinib, an FDA approved, orally administered BTK inhibitor, has demonstrated high response rates to diffuse large B-cell lymphoma (DLBCL), however, complete responses are infrequent and acquired resistance to BTK inhibition can emerge. The present study investigated the role of the platelet-deriv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Jia, Wang, Leiping, Tao, Zhonghua, Zhang, Jian, Lv, Fangfang, Cao, Junning, Hu, Xichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115192/ https://www.ncbi.nlm.nih.gov/pubmed/32186759 http://dx.doi.org/10.3892/mmr.2020.11022

Ejemplares similares

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study
por: Ji, Dongmei, et al.
Publicado: (2016)

PDGFD switches on stem cell endothelial commitment
por: Lu, Weisi, et al.
Publicado: (2022)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
por: T Low, Justin, et al.
Publicado: (2020)

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma
por: Chen, Guang-Liang, et al.
Publicado: (2022)

Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib
por: Paydaş, Semra, et al.
Publicado: (2021)

Molecular mechanisms of coronary artery disease risk at the PDGFD locus
por: Kim, Hyun-Jung, et al.
Publicado: (2023)

Molecular mechanisms of coronary artery disease risk at the PDGFD locus
por: Kim, Hyun-Jung, et al.
Publicado: (2023)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer
por: Jia, Zhenya, et al.
Publicado: (2018)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
por: Hodkinson, Brendan P., et al.
Publicado: (2020)

Radial glia require PDGFD/PDGFRß signaling in human but not mouse neocortex
por: Lui, Jan H., et al.
Publicado: (2014)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
por: He, Yizi, et al.
Publicado: (2019)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib
por: Pehlivan, Umur Anil, et al.
Publicado: (2021)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
por: Zhao, Yannan, et al.
Publicado: (2018)

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma
por: Liu, Yizhen, et al.
Publicado: (2020)

Novel TNC-PDGFD fusion in fibrosarcomatous dermatofibrosarcoma protuberans: a case report
por: Chen, Yuan, et al.
Publicado: (2021)

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane
por: Lv, Fangfang, et al.
Publicado: (2015)

miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2
por: Zhao, Mingchuan, et al.
Publicado: (2020)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
por: Zheng, Xiaohui, et al.
Publicado: (2014)

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy
por: Fox, Lucy C., et al.
Publicado: (2018)

lncRNA PITPNA-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by upregulating PDGFD
por: Yao, Jianguo, et al.
Publicado: (2023)

Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
por: Locke, Clifford B, et al.
Publicado: (2020)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma
por: Li, Jiazheng, et al.
Publicado: (2021)

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma
por: Choueiry, Fouad, et al.
Publicado: (2021)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Petrillo, Alessandra, et al.
Publicado: (2022)

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
por: Zhang, Jian, et al.
Publicado: (2022)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
por: George, Bhawana, et al.
Publicado: (2020)

GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
por: Lindholm, Kaleigh E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b4ht3g81fhuljvjhov98bs4270